Neuropeptide Y offers a new biological target for treatment-resistant depression through stress and inflammation pathways
Decreased cerebrospinal NPY levels and altered hippocampal NPY receptor expression in treatment-resistant depression patients suggest NPY restoration—via intranasal delivery or receptor-selective modulation—as a novel therapeutic approach.
Quick Facts
What This Study Found
Decreased CSF NPY in TRD patients. Reduced NPY receptor expression in stress-related brain regions. Animal models: NPY dysregulation in chronic stress with altered hippocampal signaling and HPA axis. Therapeutic targets: intranasal NPY, receptor-selective modulators.
Key Numbers
How They Did This
Narrative review synthesizing preclinical (animal stress models) and clinical (CSF biomarker, receptor expression) evidence for NPY in TRD.
Why This Research Matters
TRD affects about one-third of depressed patients and has few effective treatments. NPY represents a biologically grounded target distinct from serotonin/norepinephrine pathways targeted by conventional antidepressants.
The Bigger Picture
Moving beyond serotonin-based depression treatment toward neuropeptide targets could transform mental health care. NPY's involvement in stress, inflammation, and neuroplasticity makes it a uniquely comprehensive target for treatment-resistant cases.
What This Study Doesn't Tell Us
Review format. Clinical NPY data limited. Intranasal NPY delivery still experimental. Causation vs association for NPY decreases in TRD unclear.
Questions This Raises
- ?Will intranasal NPY clinical trials show efficacy for TRD?
- ?Which NPY receptor subtype is most important for antidepressant effects?
- ?Could NPY levels serve as biomarkers to predict TRD?
Trust & Context
- Key Stat:
- NPY depleted in TRD Decreased cerebrospinal NPY and reduced receptor expression in stress-related brain regions suggest NPY restoration as a novel antidepressant strategy
- Evidence Grade:
- Review of preclinical and clinical evidence. Good biological rationale but therapeutic applications are still experimental.
- Study Age:
- Published in 2025.
- Original Title:
- Neuropeptide Y as a multifaceted modulator of neuroplasticity, Neuroinflammation, and HPA axis dysregulation: Perceptions into treatment-resistant depression.
- Published In:
- Neuropeptides, 112, 102538 (2025)
- Authors:
- Singanwad, Priyanka, Tatode, Amol(2), Qutub, Mohammad(2), Taksande, Brijesh, Umekar, Milind, Trivedi, Rashmi, Premchandani, Tanvi
- Database ID:
- RPEP-13611
Evidence Hierarchy
Frequently Asked Questions
What is treatment-resistant depression?
TRD is depression that does not improve with standard antidepressant medications (typically after trying 2+ drugs). It affects about one-third of depressed patients and is a major unmet medical need. This review identifies neuropeptide Y as a potential new treatment target.
How could NPY help depression?
NPY regulates stress responses, inflammation, and brain plasticity—all disrupted in depression. People with TRD have lower NPY levels in their brain fluid. Restoring NPY through nasal spray delivery or drugs that activate NPY receptors could address depression through fundamentally different mechanisms than current antidepressants.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13611APA
Singanwad, Priyanka; Tatode, Amol; Qutub, Mohammad; Taksande, Brijesh; Umekar, Milind; Trivedi, Rashmi; Premchandani, Tanvi. (2025). Neuropeptide Y as a multifaceted modulator of neuroplasticity, Neuroinflammation, and HPA axis dysregulation: Perceptions into treatment-resistant depression.. Neuropeptides, 112, 102538. https://doi.org/10.1016/j.npep.2025.102538
MLA
Singanwad, Priyanka, et al. "Neuropeptide Y as a multifaceted modulator of neuroplasticity, Neuroinflammation, and HPA axis dysregulation: Perceptions into treatment-resistant depression.." Neuropeptides, 2025. https://doi.org/10.1016/j.npep.2025.102538
RethinkPeptides
RethinkPeptides Research Database. "Neuropeptide Y as a multifaceted modulator of neuroplasticit..." RPEP-13611. Retrieved from https://rethinkpeptides.com/research/singanwad-2025-neuropeptide-y-as-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.